Galectin Therapeutics
GALT
GALT
62 hedge funds and large institutions have $23.6M invested in Galectin Therapeutics in 2018 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
3.49% more ownership
Funds ownership: 10.49% → 13.99% (+3.5%)
7% more call options, than puts
Call options by funds: $1.12M | Put options by funds: $1.04M
Holders
62
Holding in Top 10
–
Calls
$1.12M
Puts
$1.04M
Top Buyers
| 1 | +$1.51M | |
| 2 | +$1.19M | |
| 3 | +$1.08M | |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$680K |
| 5 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$481K |
Top Sellers
| 1 | -$397K | |
| 2 | -$161K | |
| 3 | -$152K | |
| 4 |
NPF
Norris Perne & French
Grand Rapids,
Michigan
|
-$95.2K |
| 5 |
CCM
Courage Capital Management
Nashville,
Tennessee
|
-$94.7K |